BioSpace News Archive

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that granulocyte macrophage-colony stimulating factor (GM-CSF) gene-edited CAR-T data will be presented at the International Society for Cell & Gene Therapy (ISCT) 2021 Annual Meeting

Cloud DX and Maxwell Telecare are announcing a new partnership to bring round-the-clock virtual care and real-time vital sign monitoring to residents living in long term care facilities.

DDF shares how transitioning to virtual events and launching new initiatives helped address the immediate needs of stomach cancer patients and families.

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces positive topline results from the head-to-head phase 3 OCEAN study evaluating the efficacy and safety of melphalan flufenamide versus pomalidomide in patients with relapsed refractory multiple myeloma (RRMM).

Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it will present two posters at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2021.

Vystar Corporation Director, Ranjit K. Matthan, PhD, will deliver the opening plenary session of Rubber & Plastics News’ signature latex event, The International Latex Conference July 20-22.

Vikas Sharma, Ph.D., Shirley Lasch, and Tim O’Brien join team dedicated to developing new treatments for ALS and other genetically validated neurodegenerative diseases

- Linea™ COVID-19 SGS™ Mutation Panel Can Identify ‘Mutations of Therapeutic Concern’ that May Lessen Response to Certain Therapies - - As the Prelude to Whole Viral Genome Sequencing, Mutation Panel Empowers Pursuit of Specific Variant Lineages and Can Minimize Sequencing of Wild Type Virus - - Company Initiates Development of New Assay to Characterize B.1.617 (Indian) Variant and Sub-Variants -

Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock’s Retirement from the Company’s Board

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that its ovarian cancer vaccine technology is part of an award from the National Cancer Institute (NCI).